What's Happening At The
McGowan Institute?

November 2003 | VOL. 11 | www.McGowan.pitt.edu

LVAD Approved for "DESTINATION THERAPY"

The University of Pittsburgh Medical Center (UPMC) is among the first centers to receive approval from the Centers for Medicare & Medicaid Services (CMS) to implant left ventricular assist systems (LVAS) approved by the U.S. Food and Drug Administration (FDA) as destination therapy for heart failure patients who do not qualify for transplantation. Currently, the only FDA-approved device for destination therapy, or permanent support, is Thoratec Corporation's HeartMate XVE LVAS.

Assist devices are used most often as a bridge to transplantation. In some cases, the devices allow the heart to heal and heart transplantation is avoided. Until FDA and CMS granted approval of the HeartMate system, patients not considered candidates for transplantation did not have the option of being supported with current devices.

"This new technology will afford a number of patients with better quality of life and provide them with renewed time with family and loved ones. We are pleased to be able to offer this treatment, which marks a new era for the use of ventricular assist devices," stated Robert L. Kormos, M.D., Professor of Surgery, Director of the Artificial Heart and Cardiothoracic Transplant programs, and Medical Director of the McGowan Institute.

"For more than 15 years, our Artificial Heart Program, in conjunction with UPMC's Congestive Heart Failure Program, has been a key player in the evolving use of mechanical support. We have always kept in focus the ultimate use of these devices as replacement or destination therapy for those who do not qualify for heart transplantation," he added.

The Artificial Heart Program is one of the most experienced and active in the United States. Since its inception in 1985, the program has supported nearly 250 patients on assist devices for a period of time that equates to more than 50 years. It often serves as both a proving ground for manufacturers and a training center for surgeons from around the world. Devices that UPMC has used over the years include the Jarvik/Cardiowest Total Artificial Heart, Novacor Left Ventricular Assist Device (LVAD), Thoratec VAD and HeartMate I.

Known also for its aggressive work to enable patients on devices to be discharged to the home setting, UPMC was the first center to discharge a patient still on a device to await a human donor outside the hospital. Based on UPMC's experience, the FDA later allowed patients implanted with the Novacor to be discharged to their home to await heart transplant.

 

New Research on Nerve Agent Poisoning Antidote

Augustine Choi, M.D. will lead a $1.52 million study funded by the U.S. Department of Defense to co-develop a dry powder inhaler (DPI), which would administer an antidote for nerve agent poisoning. The system will allow more efficient self-administration of the drug atropine by American forces while under the care of military healthcare professionals.

The research will be conducted in collaboration with MicroDose Technologies, Inc., of Monmouth Junction, N.J., and will use MicroDose’s proprietary pulmonary delivery technology.

“Chemical and biological agents pose a considerable threat to American forces and potentially to other military personnel and civilians. The development of a new antidote delivery system is a crucial step in protecting personnel from these threats,” said Augustine Choi, M.D., chief of the Division of Pulmonary, Allergy and Critical Care Medicine and principal investigator of the project. “This grant will allow us to develop and test a new and improved method of protection from the effects of chemical warfare agents.”

 

COOPERATIVE RESEARCH CENTER FOR MUSCULAR DYSTROPHY

The School of Medicine is among three medical schools nationwide to be named as a cooperative center for muscular dystrophy research by the National Institutes of Health (NIH).

The centers, also at the University of Washington, Seattle and the University of Rochester School of Medicine, New York, are each being funded for five years at up to $1 million a year. The Muscular Dystrophy Association is expected to issue an announcement of available supplements to provide up to $500,000 a year for three years at each center for additional projects.

A group of some 20 congenital muscle-wasting illnesses, muscular dystrophies are caused by genetic errors in a number of muscle genes. For example, the absence of a key muscle protein called dystrophin is the reason for Duchenne muscular dystrophy (DMD), the most common, debilitating and lethal childhood muscle disease, which affects about one in every 3,000 boys, according to the advocacy group Parent Project Muscular Dystrophy.

"We will develop strategies to treat these terrible diseases that threaten children's lives and make their lives miserable," said Joseph C. Glorioso III, Ph.D., chairman of the department of molecular genetics and biochemistry and director of the Molecular Medicine Institute, principal investigator and director of the Pittsburgh center. "We also are working to find out more about the biology of these diseases." Specific projects undertaken by scientists at the University of Pittsburgh involve preclinical and clinical studies of gene and stem cell therapies to treat muscle diseases - DMD in particular.

Gene therapy will be the focus of two Pittsburgh projects. Scientists led by Xiao Xiao, Ph.D., associate professor of molecular genetics and biochemistry, will be working in collaboration with University of Missouri and Ohio State University scientists on preclinical and clinical studies to determine the most effective ways to use adeno-associated viral vectors to deliver gene therapy. Dr. Xiao and others have redesigned the virus to deliver a payload of dystrophin protein. Previous studies have shown that the virus can establish the manufacture of dystrophin in injected tissues for at least a year. However, challenges remain to determine how best to use the virus to deliver gene therapy in a systemic way.

Another Pittsburgh project, led by Johnny Huard, Ph.D., associate professor of orthopaedic surgery, molecular genetics, biochemistry and bioengineering, will attempt to deliver and engraft muscle stem cells into diseased heart tissue without causing an immune response. Dr. Huard, who also is a deputy director of the McGowan Institute for Regenerative Medicine and director of the Growth and Development Laboratory at Children's Hospital of Pittsburgh, has extensive experience in using a unique population of muscle stem cells from healthy newborn mice to deliver dystrophin, a key protein for muscle function into animal models for DMD.

Also working on the Pittsburgh team is Paul D. Robbins, Ph.D., professor of molecular genetics and biochemistry and co-director of the Pittsburgh center. These new research centers in muscular dystrophies arise from the Muscular Dystrophy Community Assistance, Research and Education Amendments of 2001, or the MD-CARE Act, passed by Congress. They will encompass basic, clinical and behavioral research projects. Centers will work individually and collaboratively, and will be overseen by a steering committee, according to the NIH. Two additional centers are expected to be funded in future years.

 

Retreat Committee Plans for 2004 Retreat

The Limbach Entrepreneurial Center is offering a 12-week course on maximizing the therapeutic and diagnostic potential of basic biomedical science discoveries. The classes will be held on Thursdays, November 6th, 2003 -- February 12th, 2004; 6PM - 9PM
To be held at the UPMC Cancer Pavilion in Shadyside

Course Highlights:
  • Recognize the Market Potential of Your Discovery

  • Protect the Value of Intellectual Property

  • Prepare your Discovery for Regulatory Pathway

  • Determine the Best Application

  • Identify Funding for Applied Research

  • Understand University Policy and Procedures

  • Engage Partners to Move your Discovery Forward

Scholarships are available for those who qualify. For more information or to request an application, please contact the Limbach Entrepreneurial Center; 412-623-3207, or via email:lec@upmc.edu

 

Retreat Committee Plans for 2004 Retreat

The 2004 McGowan Institute Scientific Retreat is scheduled for February 23-24, 2004. The program committee of Cliff Brubaker (Chair), Michael Chancellor, Ellen Cohn, Rory Cooper, Brad Keller, John Murphy, Bruno Peault, David Vorp, and Alan Wells is busy finalizing the program. On-line registration will be available in December, but in the interim, remember to Save the Date : February 23-24, 2004!

The program will include distinguished guest speakers, a poster session and 14 breakout sessions, so there will be multiple opportunities for networking and collaboration.

 

Grant Application Opportunities

Questions: Contact Jo-Anne Drabik at drabikj@upmc.edu or 412-235-5124 or Lindsay Rodzwicz at rodzwiczlj@upmc.edu or (412) 235 5157

 

Pittsburgh Life Sciences Greenhouse

Title: Technology Development Fund

APPLICATION RECEIPT DATE: January 14th, 2004

URL: http://www.pittsburghlifesciences.com/content.aspx?id=unidev

TheTechnology Development Fund is a competitive funding program designed to increase the commercialization potential of life science technologies developed by the region's scientists and entrepreneurs. The intent is to provide financial support to verify the technical and commercial feasibility of early stage inventions that will accelerate and increase the likelihood that the technology will be successfully commercialized through a regional start-up company.

 

Pittsburgh Life Sciences Greenhouse

Title: Collaborative Research Fund

APPLICATION RECEIPT DATE: January 14th, 2004

The Collaborative Research Fund (CRF) was established to support a significant portion of the cost of a company-initiated projects developed collaboratively between the firm and one or more the region's research institutions. Projects funded under this program are expected to provide access to technical expertise, facilities and capabilities not readily available in-house at the company, but which may be accessed within the academic environment. Projects must fall within the PLSG's four areas of technical focus: Drug discovery tools and targets; Medical devices and diagnostics; Therapeutic strategies for neurological and psychiatric disorders, and; Tissue/organ engineering and regenerative medicine.

 

National Institutes of Health

Title: P-20 Planning Grant: Exploratory Centers for Interdisciplinary Research

RELEASE DATE: September 30, 2003

RFA Number: RFA-RR-04-002

LETTER OF INTENT RECEIPT DATE: January 30, 2004

APPLICATION RECEIPT DATE: February 24, 2004

URL: http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-04-004.html

The collaborative nature of disciplines that characterizes multidisciplinary research is not sufficiently sustained to address, in a comprehensive and effective way, challenging problems in biomedical and behavioral research. Rather, interdisciplinary research, which integrates several disciplinary approaches in a more sustained and systematic fashion, may be required to tackle these more complex problems. Integrating different disciplines in this way holds the promise of opening up currently unimagined scientific avenues of inquiry, and in the process, may form whole new disciplines.

 

National Institutes of Health

Title: Curriculum Development Award in Interdisciplinary Research

RELEASE DATE: October 29, 2003

RFA Number: RFA-GM-04-003

LETTER OF INTENT RECEIPT DATE: January 27, 2004

APPLICATION RECEIPT DATE: February 24, 2004

URL: http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-04-007.html

The Curriculum Development Award in Interdisciplinary Research supports the development of innovative courses, curricula and educational approaches designed to train interdisciplinary scientists in emerging areas of biomedical, behavioral and quantitative sciences. These programs are focused on preparing undergraduate, predoctoral, or postdoctoral candidates, or combinations of these, to conduct research in team settings that are highly interdisciplinary and collaborative and to train future leaders who can catalyze the integration of multiple disciplines.

 

National Institutes of Health

Title: Proteomics and Metabolomics in Type 1 Diabetes and Its Complications

Release Date:October 24, 2003

RFA Number: RFA-DK-03-024

CFDA Numbers: 93.847, 93.867, 98.837, 93.855, 93.853, 93.865

URL: http://grants1.nih.gov/grants/guide/rfa-files/RFA-DK-03-024.html

Letter of Intent Receipt Date: February 18, 2004

Application Receipt Date: March 18, 2004

Purpose: The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious Diseases (NIAID), National Eye Institute (NEI), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Neurological Disorders and Stroke (NINDS), and National Institute of Child Health and Human Development (NICHD) encourage the scientific community to use proteomics technologies to study type 1 diabetes (T1D) and its complications. Proteomic technologies have been successfully used for the identification of cancer biomarkers, for the identification of novel drug targets and for studying several biological processes relevant to human health. High throughput metabolic profiling has been recently implemented for metabolomic studies. However, as of today these technologies have been applied to study T1D and its complication only in a limited way. Moreover, currently available proteomic and metabolomic technologies represent a great opportunity for advancing the field of T1D and its complications. This RFA intends to promote the use of these technologies to study T1D and its complications emphasizing the importance of collaborative efforts between investigators with expertise in proteomics or metabolomics and investigators with expertise in T1D.

National Institutes of Health

Title: Metabolomics Technology Development

Release Date: September 29, 2003

RFA Number: RFA-DK-04-001

CFDA Number:93.847

URL:http://grants1.nih.gov/grants/guide/rfa-files/RFA-DK-04-001.html

This RFA is developed as a roadmap initiative. All NIH Institutes and Centers participate in roadmap initiatives.

Letter of Intent Receipt Date: February 24, 2004

Application Receipt Date: March 24, 2004

Purpose: The Institutes and Centers of the National Institutes of Health invite applications for development and application of new technologies in metabolomics to enable research aimed at elucidating biological pathways and networks. The purpose of this initiative is to encourage the development of highly innovative and sensitive tools for identifying and quantifying cellular metabolites and their fluxes at high anatomical, spatial, and temporal resolution.

The general aim of metabolomics is to identify, measure and interpret the complex time-related concentration, activity and flux of endogenous metabolites in cells, tissues, and other biosamples such as blood, urine, and saliva. For the purposes of this solicitation, metabolites include small molecules that are the products and intermediates of metabolism, but also carbohydrates, peptides, and lipids. The need for innovative technologies for measuring and quantifying metabolites involved in cellular pathways and networks was articulated in the 2003 NIH Roadmapping Initiative. It is expected that the technologies developed under this initiative will play a major role in transferring capabilities to laboratories and research institutes that are investigating the underlying pathways involved in cellular homeostasis, perturbation, development, and aging.

Many ongoing research programs focus on development of new genomics and proteomics tools and utilization of those approaches for studying cellular function. In contrast, relatively few research programs focus on metabolomics technology development and application. This initiative is to encourage the development of highly innovative and sensitive tools for identifying and quantifying cellular metabolites and their fluxes at high anatomical resolution---extending to subcellular--- and at a temporal resolution that would be appropriate to understanding cellular processes at biologically relevant timescales. The scope of projects that would be appropriate ranges from techniques for improving and refining the process of sample separation and processing; to new methods, reagents or instrumentation for identifying and measuring metabolites and their fluxes; to the development and utilization of data reduction, management, and analysis tools needed to establish proof of principle for the technology. New technologies that, if successful, have the potential to be scalable, either as high-throughput applications or as advances that would be used in a large number of laboratories, are especially encouraged. While it is also important to develop data storage, data mining, and pathway modeling capabilities for metabolomics, these issues are explicitly not included in this particular solicitation.

 

National Institutes of Health

Title: National Centers for Biomedical Computing

Release Date: September 29, 2003

RFA Number: RFA-RR-04-001

CFDA Number: 93.389

URL:http://grants.nih.gov/grants/guide/rfa-files/RFA-RR-04-001.html

This RFA is developed as a roadmap initiative. All NIH Institutes and Centers participate in roadmap initiatives.

Letter of Intent Receipt Date: December 29, 2003

Application Receipt Date: January 23, 2004

The Institutes and Centers (ICs) of the National Institutes of Health invite applications for specialized centers in the area of biomedical computing. The U54 mechanism will be used to create NIH National Centers for Biomedical Computing (NIH NCBCs). These centers, in conjunction with individual investigator awards, will create a networked national effort to build the computational infrastructure for biomedical computing in the nation, the National Program of Excellence in Biomedical Computing (NPEBC). The establishment of the NIH NCBC was called for in the Biomedical Information Science and Technology Initiative report in 1999 ( http://www.nih.gov/about/director/060399.htm ), and their need has been reaffirmed by more recent workshops. The NIH NCBC will be devoted to all facets of biomedical computing, from basic research in computational science to providing the tools and resources that biomedical and behavioral researchers need to do their work. In addition to carrying out fundamental research, it is expected that the NIH NCBC will play a major role in educating and training researchers to engage in biomedical computing. To build the computational infrastructure for biomedical computing in the nation, the National Program will use a combination of NIH funding mechanisms that will be supported by multiple NIH Institutes and Centers. The central constituent of the NPBEC, the NIH NCBC, is the focus of this RFA. The NIH NCBC will provide tools and resources that biomedical and behavioral researchers can use at a variety of levels. The NIH NCBCs will be partnerships bringing together three types of scientists: 1) computational scientists, who invent and develop efficient and powerful languages, data structures, software architectures, hardware, and algorithms for solving biomedically significant computing problems; 2) biomedical computational scientists, who adapt and deploy resources from computational science to solve significant biomedical problems; and 3) experimental and clinical biomedical and behavioral researchers, who generate data that can be transformed into knowledge by computational simulation, analysis, modeling, data mining, and visualization. These partnerships will be designed to produce, validate, and disseminate tools and computational environments that will be useful to a broad spectrum of biomedical researchers across the nation. It is expected that the partnerships will be highly interactive. Computational scientists should work with biomedical or behavioral researchers to develop the tools while the biologists validate these tools and provide feedback for the next generation of tools. In some cases, the NIH NCBCs will enhance and extend existing tools; in other cases they will develop new tools and computational environments de novo.

Individual biomedical or behavioral investigators will make use of the NIH NCBCs in different ways. Some investigators will simply use the on-line tools and services that the NIH NCBCs provide. These investigators might never have direct contact with any researchers at the NIH NCBC, but they will download software or go to the NIH NCBC web site to make use of resources found there.

Biomedical and behavioral investigators for whom a greater level of interaction with the NIH NCBC is appropriate could follow two pathways.

1) After the initial NIH NCBCs have been funded, NIH anticipates releasing a new program announcement that will support partnerships between individual investigators and the centers. As an example, a biomedical research laboratory with software that is useful in modeling the function of the heart might seek to use the expertise of the NIH NCBC to modify the software to run on a computational grid. Alternatively, the biomedical researchers might seek support from the NIH NCBC to design and build hardware that would be well suited to solve their problems. Individual investigators should monitor the BISTI web site ( http://www.bisti.nih.gov) for relevant program announcements. It is anticipated that the announcements for partnering projects will include both new RO1's and R21's and as well as competitively reviewed supplements to existing projects.

2) Individual investigators could be part of a Driving Biological Project (DBP) funded within the NIH NCBC. These projects will be described in core 3 below. An investigator who interacts with the center in this fashion will help the NIH NCBC focus its computational research on challenging biomedical problems selected for their broad biomedical significance and compatibility with the core computational expertise of the NIH NCBC. Investigators involved in a DBP will have substantial interactions with researchers at the NIH NCBC.

Funds Available: The participating ICs intend to commit $14 million to $17 million in FY 2004 to fund 3 to 4 new centers in response to this RFA. An applicant should request a project period of 5 years. The budget (direct costs) may not exceed $3 million per year. The F&A costs (sometimes known as indirect costs) of subcontractors will not count against this $3 million limit. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size of each award will also vary. Although the financial plans of the ICs provide support for this program, awards pursuant to this RFA are contingent upon the availability of funds and the receipt of a sufficient number of meritorious applications.

 

National Institutes of Health

Title: Exploratory Centers (P20) for Interdisciplinary Research

Release Date: September 30, 2003

RFA Number: RFA-RR-04-002

CFDA Number: 93.389

URL: http://grants.nih.gov/grants/guide/rfa-files/RFA-RR-04-002.html

This RFA is developed as a roadmap initiative. All NIH Institutes and Centers participate in roadmap initiatives.

Letter of Intent Receipt Date: January 30, 2004

Application Receipt Date: February 24, 2004

Purpose: In addition to the biological sciences, biomedical research encompasses a large number of scientific disciplines, including the behavioral, quantitative, engineering and computer sciences. Distinct disciplinary perspectives represent significant sources of strength to the overall research enterprise because each discipline has its own intellectual history, experimental and analytic approaches, and theoretical context that produce a unique way of thinking about a problem. Nevertheless, as scientific capabilities move forward, increasingly complex questions arise, and these often require the convergence of perspectives from multiple disciplines. Over the years, the Institutes and Centers (ICs) of the National Institutes of Health (NIH) have developed many initiatives, mechanisms and programs to support multidisciplinary research--that is, research that brings together researchers from different disciplines to focus on a circumscribed problem.

It is becoming apparent that, in some cases, the collaborative nature of disciplines that characterizes multidisciplinary research is not sufficiently sustained to address, in a comprehensive and effective way, challenging problems in biomedical and behavioral research. Rather, interdisciplinary research, which integrates several disciplinary approaches in a more sustained and systematic fashion, may be required to tackle these more complex problems. Integrating different disciplines in this way holds the promise of opening up currently unimagined scientific avenues of inquiry, and in the process, may form whole new disciplines. Historical examples include the development of genomics, which was formed from genetics, molecular biology, analytical chemistry, and informatics. Another example in which multiple disciplines have, in a less directed way, blended and evolved into a new discipline is neuroscience. Thirty years ago, students of the brain might have identified themselves as anatomists, physiologists, or psychobiologists, but today they would consider themselves neuroscientists.

Combining particular aspects of different disciplines to develop entirely new ways to approach biomedical and behavioral research problems is daunting in many ways. In recognition of the difficulty of establishing interdisciplinary research efforts, this Request for Applications (RFA) solicits applications for P20 planning grants that will support planning activities for groups of researchers to develop interdisciplinary research strategies to solve significant biomedical and/or behavioral research problems. Activities supported will include study design and, perhaps, pilot research to demonstrate the approach to be pursued. Whatever the approach, it must integrate aspects of multiple disciplines, which will be specified by the applicants. Planning activities are intended to lay the foundation and prepare investigators for submitting a subsequent application for more substantial and longer duration support through an Interdisciplinary Research Consortium. In recognition of the need to bring several disciplines together as equal partners, this RFA allows the research team to submit separate, but related applications that will be reviewed as a unit.

 

National Institutes of Health

Title: National Technology Centers for Networks and Pathways

Release Date: September 30, 2003

RFA Number: RFA-RR-04-003

CFDA Number: 93.389

URL: http://grants.nih.gov/grants/guide/rfa-files/RFA-RR-04-003.html
This RFA is developed as a roadmap initiative. All NIH Institutes and Centers participate in roadmap initiatives.

Letter of Intent Receipt Date: February 15, 2004

Application Receipt Date: March 16, 2004

Purpose: Participating Institutes and Centers (ICs) of the National Institutes of Health invite applications for NIH National Technology Centers for Networks and Pathways (TCNP). These centers will cooperate in a networked national effort to develop highly novel, integrated, and broadly applicable proteomics technologies, to include instrumentation, biophysical methods, reagents, and infrastructure. These technologies will be specifically directed at the fundamental technological challenges inherent in acquiring quantitative information at the high anatomic resolution (subcellular) and biologically relevant timescales necessary for temporal and spatial characterization of complex biochemical pathways and molecular interactions. Beyond cataloging of proteins and their binary interactions, these methods will be directed toward quantitatively defining the dynamics of complex systems. The establishment of the TCNPs was called for in the NIH Roadmapping Initiative in 2003. TCNPs will be supported by U54 awards. The U54 awards will principally support technological innovation. However, in addition it is expected that the TCNPs will commit substantial resources to collaboration with and education of biomedical researchers, as well as the transfer of technologies to other laboratories. It is anticipated that there will be strong, vibrant interactions between the centers themselves and related individual investigator projects focused on a broad range of significant biomedical research questions. The centers should foster original and creative contributions to scientific understanding over and above that which would be obtained if each component of the center existed independently.

 

National Institutes of Health

Title: NIAMS Small Grant Program for New Investigators

Release Date: October 2, 2003

PA Number: PAR-04-002

CFDA Number: 93.846

URL: http://grants.nih.gov/grants/guide/pa-files/PAR-04-002.html

Expiration Date: October 24, 2005

Application Receipt Dates: February 24, 2004, June 24, 2004, October 22, 2004

Purpose: The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is seeking small grant (R03) applications to stimulate and facilitate the entry of promising new investigators into areas of research of interest to the NIAMS. This solicitation will provide support for pilot research that is likely to lead to a subsequent individual research project grant (R01).

Research Objectives: The NIAMS Small Grant program is designed to facilitate the entry of promising new investigators into research on arthritis and musculoskeletal and skin diseases and injuries. Brief summaries of the focuses of the NIAMS' Extramural Program branches are listed below. For more detailed information about scientific areas of interest to the NIAMS, applicants are encouraged to refer to the NIAMS website at http://www.niams.nih.gov .

Summary

Rheumatic Diseases: The mission of the Rheumatic Diseases Branch is to promote and support research leading to prevention, diagnosis and cure of rheumatic and related diseases. The Branch supports basic, epidemiologic, and clinical research on etiology, pathogenesis, course, interventions, and outcomes in rheumatic and related diseases.

Muscle Biology: The Muscle Biology Branch encourages and supports research on skeletal muscle, its diseases and disorders, and its central role in human physiology and exercise. Topics include the molecular structure of muscle and the molecular mechanisms that produce force and motion. One focus of this program is understanding the alterations in muscle resulting from increased exercise regimens and, conversely, the atrophy that follows immobilization during injury or illness.

Musculoskeletal Diseases: This Branch supports studies of the skeleton including bones, joints and associated connective tissues. Broad areas of interest include skeletal development, metabolism, mechanical properties, and responses to injury. Clinical and basic research in the areas of osteoporosis and orthopaedic sciences are of particular interest under this program. Other musculoskeletal disorders of interest include osteoarthritis, osteogenesis imperfecta, and Paget's disease. The Program supports research in the area of acute and chronic injuries of the musculoskeletal system including work related and repetitive stress injuries. Research proposals related to the development of new technologies with the potential to improve treatment and/or diagnosis of skeletal disorders and to facilitate the repair of trauma in the normal skeleton are of great interest. In addition, bioengineering, sports medicine and musculoskeletal fitness are areas of special research emphasis.

Skin Diseases: This Branch supports basic and clinical studies of the skin in normal and disease states. The wide range of skin diseases under study with NIAMS support includes keratinizing disorders such as psoriasis and ichthyosis, atopic dermatitis and other chronic inflammatory skin disorders, the vesiculobullous diseases such as epidermolysis bullosa and pemphigus, acne, and vitiligo.


National Institutes of Health

Title:Collaborative Arthritis and Musculoskeletal and Skin Diseases Science Award (CAMSSA)

Release Date: October 2, 2003

PA Number: PAR-04-003

CFDA Number: 93.846

URL: http://grants1.nih.gov/grants/guide/pa-files/PAR-04-003.html

Expiration Date: October 1, 2006, unless reissued.

PURPOSE: The objective of the Collaborative Arthritis and Musculoskeletal and Skin Diseases Science Award (CAMSSA) program is to develop and promote competitive scientific research programs in areas within the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases at institutions with substantial minority enrollment. The CAMSSA program is designed to encourage collaborative investigations among scientists at institutions with substantial minority enrollment with grantees from research-intensive institutions who have grant support to conduct research in arthritis, musculoskeletal diseases or skin diseases. The nature of the collaborations will include joint research efforts, specialized training in research techniques, and participation in research seminars. The CAMSSA program should develop and expand scientific opportunities among the participating institutions for research in arthritis, musculoskeletal diseases or skin diseases.

Research Objectives: Characteristics of the CAMSSA Program: The CAMSSA will support an investigator-initiated research project in which the applicant and a collaborating scientist will work in a clearly defined area of mutual research interest related to arthritis, musculoskeletal diseases or skin diseases. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant and the collaborator. Since the intent of the award is to develop competitive research programs at institutions with substantial minority enrollment, the applicant and collaborating investigators must document the potential for developing scientific approaches to accomplish the objectives of the proposed research project. The project must consist of a scientifically meritorious research plan that involves an efficacious collaborative effort among the participating investigators, each of whom will be conducting a portion of the total research project in his/her own laboratory. Examples of the collaborative interactions include the sharing of ideas, data, and exchanging of research techniques and expertise. It is anticipated that collaboration between the institutions will provide training opportunities for pre- and postdoctoral fellows at both institutions.

Consortium arrangement between the applicant institution with substantial minority enrollment and the collaborating research-intensive institution: Each of these institutions must provide the appropriate facilities and resources for the applicant and collaborating investigators to accomplish the goals of the proposed research program. The CAMSSA requires effective research collaboration among these investigators, who must be full-time employees of their respective institutions. These investigators must provide a detailed description of the nature and the extent of the research collaboration such that the necessary administrative and fiscal considerations are fully explained in the application. There must be letters from the applicant and collaborating institutions that signify their intent to participate and to provide the necessary resources proposed in the application. The minority-serving institution must allow the applicant a minimum 50% reserved time to devote to the specific aims of the proposed research during the academic year. The collaborator must indicate in the application the percent effort that will be contributed to the proposed research project.

Before developing the application, the applicants should obtain a copy of the latest published policy governing consortia in the NIH Grants Policy Statement (3/01).

The NIAMS strategic plans for fiscal years 2000-2004 and for health disparities focus on a multidisciplinary approach to accomplish goals of " Healthy People 2010" as they relate to diseases that affect bones, joints, muscles, and skin. Priority areas outlined in these strategic plans may be reviewed at http://www.niams.nih.gov/an/stratplan/index.htm .


National Institutes of Health

Title: Proteomics in Aging and Age-Related Disorders

Release Date: October 07, 2003

RFA Number: RFA-AG-04-006

CFDA Number: 93.866

URL: http://grants1.nih.gov/grants/guide/rfa-files/RFA-AG-04-006.html

Letter of Intent Receipt Date: January 23, 2004

Application Receipt Date: February 23, 2004

Purpose: The National Institute on Aging (NIA) is soliciting applications that use proteomic approaches to study age-related changes in protein structure and function. Proteomics research is expected to provide significant insights into the cellular and molecular mechanisms of aging and age-associated disease processes. This Request for Applications (RFA) encourages projects that advance research to identify and quantitate protein expression patterns, post-translational modification of proteins, and protein-protein interactions which may change in cells or tissues as a direct result of the aging process or age-related pathology. Research projects that take advantage of various animal models of aging and of age-related human disease, and that focus on cells or tissues of aging physiological systems, such as the cardiovascular, musculoskeletal, immune, endocrine and nervous systems, are encouraged.


National Institutes of Health

Title: High Risk Rheumatic and Musculoskeletal and Skin Diseases Research

Release Date: October 16, 2003

RFA Number: RFA-AR-04-002

CFDA Number: 93.486

URL: http://grants2.nih.gov/grants/guide/rfa-files/RFA-AR-04-002.html

Letter of Intent Receipt Date: November 17, 2003

Application Receipt Date:December 16, 2003

Purpose: The purpose of this initiative is to broaden the base of inquiry in fundamental biomedical, biobehavioral, and biomedical technology research by encouraging applications for research projects that involve an especially high degree of innovation and novelty and, therefore, require a preliminary test of feasibility. The goal is to solicit research applications with the potential for developing groundbreaking technology or methodology that may lead to significant expansion of biomedical research horizons, precipitate a paradigm shift in research, or lead to substantial improvements in human health. Research projects proposed under this Request for Applications (RFA) may involve substantial experimental risks such that their potential for highly significant outcomes may be difficult to judge by the standard criteria used in evaluating investigator initiated (R01) proposals. Preliminary data are not required. The work proposed may not overlap with the aims of currently supported projects or those in which the Principal Investigator has participated during the past five years. Proposed projects must support the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).

Two kinds of experienced and established investigators are sought. First, experienced and established investigators in rheumatic or musculoskeletal or skin diseases are encouraged to present a proposal for testing the feasibility of a novel idea, resource or technology. The project should represent a clear and distinctly different approach from the investigator's current and previous (past 5 years) research. Second, experienced and established investigators with no previous work in rheumatic or musculoskeletal or skin diseases are encouraged to apply their expertise to research that is relevant to rheumatic or musculoskeletal or skin diseases. This request for applications should not be considered for new investigators without previous grant experience.

Naval Research Laboratory
Broad Agency Announcement

Title: Research in Bio/Molecular Science and Engineering

BAA Number: BAA 69-03-01

URL: http://heron.nrl.navy.mil/contracts/baa.htm

The Center for Bio-Molecular Science and Engineering (Code 6900) of the Naval Research Laboratory (NRL) conducts multidisciplinary research in biotechnology using the techniques of modern molecular biology, biophysics, chemistry, microelectronics, and engineering to fabricate biosensors, biomaterials, and advanced systems.Current research areas include:

(1) Biophysical chemistry of membranes.
(2) Research into biosensors including construction of novel devices, accessories for automated reagent delivery, production of biomolecular recognition elements or configuration of bioassays for integration into the sensor. Targets of detection include explosives, pollutants, pathogens, toxic agents, and hazardous chemicals.
(3) Genetic and tissue engineering of biomaterials.
(4) Self assembled films and patterns for advanced material development.
(5) Liposomal delivery of vaccines and pharmaceuticals.
(6) Physical characterization of thin films and surfaces.
(7) Microwave devices, ultramicroelectrodes and electron emitters based on metallized composites. Microwave materials based on nanodimension powders and metallized composites.
(8) Self-assembly of microstructures for advanced materials, including tubules, advanced ceramics and ceramic solgels, and the assessment of potential applications including: controlled release, advanced composites for electronic, structural, and thermal applications, and environmental applications.
(9) Selective patterning of biological materials (proteins, cells, nucleic acids) on solid substrates.
(10) research item deleted
(11) research item deleted
(12) Development of novel lithographic, patterning, and/or metallization processes for high resolution imaging, fabrication of advanced microelectronic or nanoelectronic devices, displays, biosensors, multilayers, or three dimensionally structured materials.
(13) Advanced materials using liquid crystals and ordered polymers, relation between molecular structure and material properties, assessment of their properties for potential applications in the areas of real time holography, ferroelectric phenomena, high resolution display, pryoelectric sensors, and piezoelectric materials, electro-optic materials, non-linear optics, and optical wave guiding.
(14) Self-assembly of nano-scale structures such as bicontinuous cubic phase and assessment of their use for technological applications in the areas of controlled release, encapsulation, and nanocomposites.
(15) Remediation of oily and contaminated water using physical or phase- separation processes. The NRL is inviting Initial Proposals for applied and basic research in areas closely related to and supportive of these programs. It is expected that multiple projects may result with each targeted to a particular technology or application area.

Address Initial Proposals to Code 6902, e-mail <mailto:mas@cbmse.nrl.navy.mil> , telephone (202) 404-6015. Allow one month before requesting confirmation of receipt of Initial Proposal, if confirmation is desired. Substantive contact should not take place prior to evaluation of an Initial Proposal by NRL. If necessary, NRL will initiate substantive contact.

 

National Science Foundation, Directorate for Education and Human Resources, Division of Undergraduate Education

Title: NSF Computer Science, Engineering, and Mathematics Scholarships (CSEMS)

Date Posted: October 14, 2003

Program Solicitation Number: NSF 04-506     Replaces Document NSF 03-501

CFDA Number: 47.076--- Education and Human Resources

URL: http://www.nsf.gov/pubs/2004/nsf04506/nsf04506.htm

Letter of Intent Due Date (optional): December 03, 2003

Full Proposal Deadline (due by 5 p.m. proposer's local time): January 28, 2004

Synopsis of Program: This program supports scholarships for academically talented, financially needy students, enabling them to enter the high technology workforce following completion of an associate, baccalaureate, or graduate level degree in computer science, computer technology, engineering, engineering technology, or mathematics. Academic institutions apply for awards to support scholarship activities, and are responsible for selecting scholarship recipients, reporting demographic information about student scholars, and managing the CSEMS project at the institution. 

Organization Limit: Institutions of higher education (as defined in section 101 (a) of the Higher Education Act of 1965) in the United States and its territories that grant associate, baccalaureate or graduate degrees in computer science, computer technology, engineering, engineering technology, or mathematics are invited to submit proposals. 

PI Eligibility Limit: The Principal Investigator must be a faculty member currently teaching within one of the CSEMS disciplines who can provide the leadership required to ensure the success of the project. Projects involving more than one department within an institution are eligible, but a single Principal Investigator must accept overall management responsibility. Other members of the CSEMS project management team may be listed as Co-Principal Investigators. 


National Science Foundation, Directorate for Education and Human Resources, Division of Elementary, Secondary and Informal Education

Title: Centers for Learning and Teaching (CLT)

DatePosted: Posted October 03, 2003

Program Solicitation Number: NSF 04-501     Replaces Document NSF 02-522

CFDA Number: 47.076--- Education and Human Resources

URL: http://www.nsf.gov/pubs/2004/nsf04501/nsf04501.htm

Preliminary Proposal Due Date(s) (required): December 02, 2003 (due by 5 p.m. proposer's local time), November 10th, annually, thereafter.

Full Proposal Deadline(s)(due by 5 p.m. proposer's local time): February 20, 2004 and February 20th, annually, thereafter.

Synopsis of Program: The Centers for Learning and Teaching (CLT) program focuses on the advanced preparation of science, technology, engineering, and mathematics (STEM) educators, as well as the establishment of meaningful partnerships among education stakeholders, especially Ph.D.-granting institutions, school systems, and informal education performers.  Its goals are to renew and diversify the cadre of leaders in STEM education; to increase the number of K-16 educators capable of delivering high-quality STEM instruction and assessment; and to conduct research into STEM education issues of national import (e.g., the nature of learning, teaching strategies, and reform policies and outcomes).

Estimated Number of Awards: Anticipated Funding Amount: $4,000,000 in Fiscal Year 2004, pending availability of funding - $2,000,000 will be allocated per year per Center - award duration will be up to 5 years.


National Science Foundation

Announcing the 2004

Alan T. Waterman Award

The Alan T. Waterman Award is the highest honor awarded by the National Science Foundation. Since 1975 when Congress established the Award to honor the Foundation's first Director, the annual Award has been bestowed upon individuals who have demonstrated exceptional individual achievement in scientific or engineering research of sufficient quality to place them at the forefront of their peers.

The purpose of the award is to recognize outstanding young researchers in any field of science or engineering supported by the Foundation. The Awardee receives a $500,000 nonrestrictive grant over a 3-year period for continued research.

Who is eligible:Candidates must be U.S. citizens or permanent residents and must be 35 years old or younger, or not more than seven years beyond receipt of the Ph.D. by December 31, 2003. Criteria include originality, innovation and significant impact on the field.

How to Apply:Nominations for the 2004 Award may be made through the National Science Foundation's FastLane at https://www.fastlane.nsf.gov/honawards.

Program Contact:
Susan E. Fannoney
Alan T. Waterman Award Committee
National Science Foundation
4201 Wilson Blvd. Rm 1220
Arlington, VA 22230
Phone: 703-292-8096
Email: sfannone@nsf.gov
URL: http://www.nsf.gov/nsb/awards/waterman/waterman.htm
Deadline for Submissions: December 31, 2003

Doris Duke Charitable Foundation
Title: Distinguished Clinical Scientist Award for “Bench to Bedside” Translational Research
URL: http://ddcf.aibs.org/dcsa/index.asp

The purpose of the Doris Duke Distinguished Clinical Scientist Award (DCSA) Program is to recognize outstanding physician-scientists who are engaged in applying the latest basic science advances to the prevention, diagnosis, treatment, and cure of disease, and to enable the physician-scientist to support and mentor the next generation of physician-scientists conducting translational clinical research.

As the pressures on physician-scientists increase, it becomes more and more difficult to maintain focus on the broad research picture. This is true, unfortunately, at a time when it is more important than ever to connect basic and clinical research. Recent discoveries made by basic scientists need to be moved through clinical research to the prevention, diagnosis, treatment, and cure of disease. Awardees are expected to have had and continue to have an impact in their institution and in their research field in bridging the gap between bench science and clinical research and to promote the development of a new generation of physician-scientists who can serve that role.

Doris Duke Distinguished Clinical Scientist awards were granted to four physician-scientists in 1999, to seven physician-scientists in 2000, to seven physician-scientists in 2001, and to five physician-scientists in 2002.

In 2004, up to four awards of up to $1.5 million will be granted to physician-scientists conducting translational clinical research in ANY disease area. Unlike previous years, this award cycle is not limited to specific disease areas. See 2004 RFP (below) for eligibility criteria. Once the RFP has been reviewed, questions about the DCSA program should be sent via e-mail to ddcf@aibs.org .

The Foundation is currently accepting nominations for the 2004 Distinguished Clinical Scientist Award competition. Nominations are solicited from accredited U.S. academic medical centers and other U.S. non-profit research institutions. Nominee's applications will be reviewed by Expert Panels in a multi-staged process. Nominations are due by December 10, 2003 . See 2004 RFP at http://ddcf.aibs.org/dcsa/resources/DCSA2004_RFP.pdf for eligibility criteria and nomination instructions.

 

Brain Tumor Society

Title: Basic Science Brain Tumor Research Grants

Deadline: April 17, 2004

Deadline Note: Anticipated deadline. The record will be updated when new program information becomes available.

Funding : Upper amount of $200,000. Grants are awarded annually for up to a two-year period, at a maximum of $100,000 per year. Funds may be used for start up projects or supplementary funding. Funds will not be granted for indirect costs.

Eligibility: Applications may be submitted by public and private institutions, such as hospitals, universities, colleges, and laboratories. Principal investigators must be faculty at the instructor level or higher. Grants are available for basic scientific brain tumor research conducted in the United States of America. Researchers do not have to be citizens of the United States to apply and receive funding.

Abstract: The Brain Tumor Society invites applications for basic scientific research on brain tumors directed at finding a cure. Any project with the potential to advance basic scientific brain tumor research will be considered. Clinical projects will not be funded.

Contact:
Carrie Treadwell, Grants Manager
Brain Tumor Society
124 Watertown Street, Suite 3-H
Watertown, MA 02472
Phone: (800)770-8287, ext. 10 or (617) 924-9997
Fax: (617)924-9998
Email: grants@tbts.org
URL: http://www.tbts.org/resfund.htm

 

United Cerebral Palsy Research and Educational Foundation

Title:Research Grant Program

Deadline Note:Continuous. All applications are peer reviewed throughout the year for scientific merit, significance, and relevance; grants are awarded on a competitive basis twice a year. Interested parties should contact the foundation to request an application.

Funding:Upper amount of $100,000. Research funds are available in amounts up to $50,000 a year for each of two years.

Eligibility:On occasion when there is a unique opportunity, funds are awarded to investigators outside the USA.

Abstract: Research funds are available on a competitive basis to investigators in the United States of America for pilot studies. Research is supported that is important for the prevention of cerebral palsy and for improvement in the quality of life of persons with disabilities due to cerebral palsy and related neuro-developmental motor disorders. Research can be laboratory oriented, studies of a defined population group, or community based.

Contact: United Cerebral Palsy Research and Educational Foundation
1660 L Street, NW, Suite 700
Washington, DC 20036
Phone: (800)872-5827, ext. 7140
Email: lsmithslade@ucp.org
URL: http://www.ucp.org/ucp_generaldoc.cfm/1/4/23/23-23/113

 

Arnold and Mabel Beckman Foundation

Title: Beckman Young Investigators Program

Deadline: October 01, 2004

Deadline Note: Anticipated deadline. The record will be updated when new program information becomes available. The application must be received by 5:00 P.M. PST on the deadline date.

Funding: Upper amount of $240,000. Projects are normally funded for a period of three years. When extraordinary circumstances warrant, support may be provided over a one-year or four-year period. Grants are normally in the range of $240,000 over the term of the project. The foundation does not provide for overhead or for indirect costs.

Eligibility:To be eligible, an applicant should not have completed more than three full years in his or her tenure-track or other comparable independent research appointment on the anniversary date of initial appointment in the year in which the application is to be made. Regardless of eligibility under this rule, no individual may apply for a Beckman Young Investigator award more than three times.
The program is open to persons with tenure-track appointments in academic and nonprofit institutions that conduct fundamental research in the chemical and life sciences. Candidates must be citizens or permanent residents of the United States at the time of application. Documentation of permanent residency status must be provided with the application. Persons who have applied for permanent residency but have not received their government documentation by the time of application are not eligible.
Funding will not be considered for the following:

  • General institutional expenses
  • General fundraising campaign expenses, such as dinners and mass mailings
  • As a contribution to unified funds or to a pooled fund that is itself used to award grants of any kind
  • Social science, religious, political, or other research that does not fall within the foundation's areas of interest

Abstract: The Arnold and Mabel Beckman Foundation makes grants to nonprofit research institutions to promote research in chemistry and the life sciences, broadly interpreted, and particularly to foster the invention of methods, instruments, and materials that will open up new avenues of research in science.
The Beckman Young Investigators Program provides research support to promising young faculty members in the early stages of academic careers in the chemical and life sciences. Proposed research should represent innovative departures in research rather than extensions or expansions of existing programs. Interdisciplinary research is encouraged.

Programs Administrator
Arnold and Mabel Beckman Foundation
100 Academy Drive
Irvine, CA 92612
Phone: (949)721-2222
Fax:(949)721-2225
Email:
younginvestigators@beckman-foundation.com
URL: http://www.beckman-foundation.com/byiguide.html

 

Elsa U. Pardee Foundation

Title: Cancer Research Grants

Deadline Note: Continuous. Applications are accepted throughout the year.

Application forms are available on written request and must accompany all project proposals.

Funding: In 2000, grants ranged from $8,000 to $525,000.

Abstract:The Elsa U. Pardee Foundation makes grants for projects related to the cure and control of cancer, and in general does not provide for building funds, equipment (except that used in a specific project), fellowships, or fundraising campaign contributions. The foundation particularly welcomes innovative, small-scale, short-term projects that may be difficult to fund elsewhere. An attempt is made to initiate several new projects each year as other projects are concluded.

Contact: Lucille Dougherty, Staff Assistant
Elsa U. Pardee Foundation
P.O. Box 2767
Midland, MI 48641-2767
Phone: (989)832-3691
Email: info@pardeefoundation.org
URL: http://www.pardeefoundation.org/process.htm

 

Cystic Fibrosis Foundation (CFF)

Title: Therapeutics Development Grants

Deadline Note: Continuous. There are no deadlines.

Funding: $100,000

Upper Amount: $1,500,000. Component I awards will be up to $100,000 per annum for a maximum of two years. Component II awards will be up to $750,000 per annum for a maximum of two years of support. Funds will be provided for research prior to, but not including, Phase III clinical trials.

Abstract: The Cystic Fibrosis Foundation (CFF) has announced its Therapeutics Development Grants program. The purpose of this program is to provide funds to businesses that will develop commercial products to benefit individuals with Cystic Fibrosis (CF). First, the grantee will examine the scientific potential of new products under Component I. Component II studies will involve support for the continuation of Component I developments and the initiation of patient clinical studies.

Contact: Office of Grants Management
Cystic Fibrosis Foundation
6931 Arlington Road, 2nd Floor
Bethesda, MD 20814
Phone: (800)344-4823
Fax: (301)951-6378
Email: info@cff.org
URL: http://www.cff.org/research/therapeutics_development_program.cfm

 

Pew Charitable Trusts, Health and Human Services, National Program

Title: Biomedical Research and Training

Deadline Note: Continuous. The sponsor does not have deadlines governing the submission of proposals. Letters of inquiry are accepted throughout the year and reviewed on a rolling basis. If a proposal is considered appropriate for board review, it will be slated for the next available opening on a board agenda. The board meets quarterly, usually in March, June, September, and December.

Funding: The award amount is unspecified. Although grant size varies from program to program, the median size in the past year was $200,000. Generally speaking, smaller grants are made in those programs that work more closely with community-based and direct service organizations. Larger grants are made in programs that work with larger organizations such as research, academic, and health institutions.

Eligibility: The sponsor makes grants only to organizations that are classified as tax exempt under section 501(c)(3) of the Internal Revenue Code and as public charities under section 509(a) of that code. The sponsor does not make grants to individuals or to for-profit organizations.

Abstract: The goal of this initiative is to promote continued excellence in biomedical research in the United States and to develop research in Latin America by supporting outstanding, competitively selected biomedical scientists and fostering interdisciplinary biomedical research. This program strives to fill needs in the biomedical research community that are not sufficiently addressed by other funding sources, particularly by the National Institutes of Health.
The objectives are to provide flexible support to outstanding beginning faculty, helping to establish their research careers and providing them with an opportunity to pursue innovative new lines of work and to promote research excellence in Latin American countries by establishing a critical mass of well- trained investigators in those countries.

Contact:
Pew Charitable Trusts
2005 Market Street, Suite 1700
Philadelphia, PA 19103-7077
Phone: (215)575-9050
Fax: (215)575-4939
Email: info@pewtrusts.com
URL: http://www.pewtrusts.com/grants/grants_item.cfm?image=img3&page=g3&program_area_id=4#biomed


United States Department of Defense (DOD)
UnitedStates Special Operations Command (USSOCOM)

Title: Broad Agency Announcement for Biomedical Research

DeadlineContinuous. Pre-proposals may be submitted until April 30, 2005.

Abstract: The U.S. Special Operations Command is soliciting pre-proposals directed at basic and applied biomedical research focusing on Special Operations Forces (SOF)-relevant aspects of medical care, particularly related to combat casualty management; medical aspects of mission planning, biomedical training, environmental protection, vibration/shock injury, nutrition, hydration, diving procedures equipment and injuries, exercise and mission related physiology, field diagnostic and care equipment; and medical information management systems.

The following general topic areas of basic and applied biomedical research are of interest:
  • casualty management;

  • card diagnostics, micro labs, and rapid assays;

  • enhanced mass casualty response;

  • advanced resuscitative fluid studies;

  • rapid wound tissue regeneration;

  • medical aspects of mission planning;

  • medical aspects of foreign internal defense (FID) missions;

  • integrated and automated pre-mission and enroute medical hazard and threat identification, assessment and mitigation;

  • medical aspects of environmental/thermal protection;

  • thermal protection in dive/overland transition operations;

  • extreme environment acclimatization schedules;

  • integration of improved body armor with thermal protection, survival gear and nuclear biological chemical (NBC) protection;

  • sustained thermal protection while encapsulated;

  • medical administration of nutrition and hydration;

  • mission performance enhancements in extreme environments;

  • post NBC exposure administration and treatments;

  • exercise and mission-related physiology;

  • pain suppression modalities in special operations;

  • human performance enhancements/mission extenders;

  • prevention of musculoskeletal injuries;

  • preventive medicine;

  • acoustic protection, enhancement, and treatments;

  • pharmacological interventions; and

  • rapid assays and diagnostics.


Contact: Mr. John Thompson
United States Special Operations Command
Headquarters Procurement Division
7701 Tampa Point Boulevard
MacDill Air Force Base, FL 33621-5323
Phone:(813)828-7077
Fax: (813)828-7504
Email: thompsj@socom.mil
URL: http://fedbizopps.cos.com/cgi-bin/getRec?id=20030421a7

 

Departmentof Health and Human Services (DHHS), National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)

Title: Role of Antioxidants in the Prevention of Diabetic Complications – NHLBI

PA Number: PA-01-112

Deadline: October 01, 2003; February 01, 2004; June 01, 2004

Deadline Note: The final receipt date for applications submitted in response to this program announcement will be October 1, 2004, unless reissued.

Funding: The award amount for the R01 is unspecified. The total project period for an R01 application submitted in response to this PA may not exceed five years. Applicants for the R21 must limit their requests to $125,000 in direct costs per year and are limited to two years.

Eligibility: Applications may be submitted by domestic and foreign, for-profit and nonprofit organizations, public and private, such as universities, colleges, hospitals, and laboratories; units of state and local governments; and eligible agencies of the federal government.

Abstract: The National Heart, Lung, and Blood Institute (NHLBI) has identified specific areas of special interest to pursue in the following fields: biology of adhesion molecules, developmental genes, emerging infections, gene transfer and therapy, immunomodulation of tissue transplantation, impact of stress on disease, biology of hematopoiesis, neuromuscular interactions, and tissue injury. The main areas of research that concern NHLBI are sponsored by its Heart and Vascular Diseases Program, Lung Diseases Program, Blood Diseases and Resources Program, Epidemiology and Clinical Applications Program, and National Center on Sleep Disorders Research.

The NHLBI seeks basic and clinical research applications to study the use of vitamin E and other antioxidants in the prevention or amelioration of diabetic complications.
Prevention and treatment of long-term micro- and macrovascular complications remain critical problems in the management of type 1 or type 2 diabetes mellitus. A growing body of in vitro and in vivo research indicates that hyperglycemia leads to increased oxidative stress and endothelial dysfunction. In addition, numerous studies have suggested that patients with diabetes appear to have decreased antioxidant defense capability, measured as lower levels of specific antioxidants, such as ascorbic acid (vitamin C) or vitamin E, or reduced activities of antioxidant enzymes, such as catalase, superoxide dismutase, or glutathione peroxidase.

This program announcement (PA) solicits applications to determine the efficacy of vitamin E or other antioxidants in preventing, delaying, or ameliorating the micro- or macrovascular complications of diabetes, and to provide insight into the mechanisms by which antioxidants might prevent or influence the development of diabetic vascular disease.

Appropriate topics for investigation under this PA would include, but are not limited to,
  • preclinical studies to determine the mechanisms by which antioxidants prevent or influence the development of diabetic vascular disease, including neurovascular and cerebrovascular disease;
  • studies to define interactions between oxidative pathways and free radical formation and the signaling pathways by which insulin, glucose, and other factors affect the endothelium;
  • studies to investigate genetic factors that may affect susceptibility to oxidative damage and response to antioxidant therapies in people with diabetes;
  • studies to define similarities and differences in the mechanisms by which oxidative stress and antioxidant therapies affect microvascular and macrovascular disease in diabetes;
  • phase II studies to assess metabolism and tissue distribution, determine kinetics, and establish optimal dosing regimens for vitamin E or other antioxidants in patients with diabetes or diabetic complications;
  • studies to establish valid surrogate markers or clinical endpoints of diabetic complications that could be used in phase III trials of antioxidants;
  • studies to determine clinically meaningful, state-of-the art measures of oxidant or antioxidant status of patients with diabetes;
  • small trials to compare antioxidants to establish which ones are most likely to be efficacious in diabetic complications, or to define specific subpopulations who are most likely to benefit from antioxidant intervention; and
  • studies to develop new strategies to inhibit oxidation or glycoxidation and examine the effect of these strategies on microvascular or cardiovascular disease.

This PA will use the National Institutes of Health (NIH) research project grant (R01) and the exploratory/development research grant (R21) award mechanisms.

Contact: Momtaz Wassef, Ph.D.
National Heart, Lung, and Blood Institute
Division of Heart and Vascular Diseases
6701 Rockledge Drive, Suite 10186
Bethesda, MD 20892-7956
Phone: (301)435-0550
Fax: (301)480-2848
Email: mw47d@nih.gov
URL: http://grants.nih.gov/grants/guide/pa-files/PA-01-112.html

 

Department of Health and Human Services (DHHS), National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)

Title: Bioengineering Research Grants – NHLBI

PAR Number: PAR-02-011

Deadline: February 01, 2004June 01, 2004October 01, 2004

Deadline Note: This program announcement expires on October 1, 2004, unless reissued.

Eligibility: Applications may be submitted by domestic for-profit and nonprofit organizations, public and private. Examples of eligible organizations include universities, colleges, hospitals, national laboratories, industrial research organizations, large or small businesses, units of state and local governments, eligible agencies of the federal government, and faith-based organizations. Foreign institutions are not eligible to apply.

Abstract: The National Heart, Lung, and Blood Institute (NHLBI) has identified specific areas of special interest to pursue in the following fields: biology of adhesion molecules, developmental genes, emerging infections, gene transfer and therapy, immunomodulation of tissue transplantation, impact of stress on disease, biology of hematopoiesis, neuromuscular interactions, and tissue injury. The main areas of research that concern NHLBI are sponsored by its Heart and Vascular Diseases Program, Lung Diseases Program, Blood Diseases and Resources Program, Epidemiology and Clinical Applications Program, and National Center on Sleep Disorders Research.

Participating institutes and centers (ICs) of the National Institutes of Health (NIH) invite applications for R01 awards to support Bioengineering Research Grants (BRGs) for basic and applied multidisciplinary research that addresses important biological or medical research problems. The BRGs support multidisciplinary research performed in a single laboratory or by a small number of investigators that applies an integrative, systems approach to develop knowledge or methods to prevent, detect, diagnose, or treat disease or to understand health and behavior. A BRG application may propose hypothesis-driven, discovery-driven, developmental, or design-directed research at universities, national laboratories, medical schools, large or small businesses, or other public and private entities.

The mechanism of support will be the NIH R01 research grant.
Contact: Christine A. Kelley, Ph.D.
National Heart, Lung, and Blood Institute
Division of Heart and Vascular Diseases
6701 Rockledge Drive, Room 9142
Bethesda, MD 20892
Phone: (301) 435-0513
Fax:(301)480-1336
Email: kelleyc@nhlbi.nih.gov
URL: http://grants.nih.gov/grants/guide/pa-files/PA-02-011.html